Are generic and brand-name statins clinically equivalent? Evidence from a real data-base

Corrao, Giovanni; Soranna, Davide; Arfè, Andrea; Casula, Manuela; Tragni, Elena; Merlino, Luca; Mancia, Giuseppe; Catapano, Alberico L.

doi:10.1016/j.ejim.2014.08.002

Cited by 42 publications

(47 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, price competition can be achieved when coordinated demand and supply-side policies are considered [8]. Care is not compromised with demonstrated bioequivalence between generics and originators [1,2,[52][53][54]. Supply-side measures such as price cutting are relatively easy to implement in Korea but the lack of demand-side measures appears insufficient to create a competitive market.…”

Section: Discussionmentioning

confidence: 97%

The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs

Kwon

Kim

Godman

et al. 2015

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs

Kwon

Kim

Godman

et al. 2015

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…successful switching of patients between higher priced patented and generic statins to save considerable resources without compromising care [18][19][20][21]. Cost considerations are increasingly important especially with the growing prevalence of non-communicable diseases including diabetes, hypertension, and obesity and generic statins priced as low as 2% to 4% of pre-patent loss prices in some countries [3,[22][23][24] .…”

Section: Introductionmentioning

confidence: 99%

Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future

et al. 2016

View full text Add to dashboard Cite

This version is available at https://strathprints.strath.ac.uk/54803/ Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.ukThe Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the management and persistent access to Strathclyde's intellectual output. Atorvastatin was the most prescribed statin, followed by simvastatin, rosuvastatin and finally fluvastatin. Prescribed doses were less than 1 defined daily dose in the majority, with high use of originators.

show abstract

“…The competition between brand-name drugs and generics is becoming fiercer than ever before in the world, especially with the increase of newly approved generics in developing countries. Although domestic drugs (i.e., generics) have been verified bioequivalence to the originator (imported-joint venture drugs) in many published studies (Paton, 2006; Sakshaug et al, 2007; Kesselheim et al, 2008, 2010; Corrao et al, 2014a,b; Gagne et al, 2014; Lessing et al, 2014; Martin et al, 2014), quite a lot of patients in China still prefer brand-name drugs. Compared with the situation in China, foreign countries have different attitudes to generic drugs.…”

Section: Discussionmentioning

confidence: 99%

Drug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients

Cai

Zhang

et al. 2017

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Patient's response to drug brand is a comprehensive physiological and psychological effect which might impact the compliance and efficacy of drugs. Whether the therapeutic outcome altered on patients with brand response after they experience drug switch is not clear.Methods: 459 outpatients with mild-to-moderate depression were divided into the imported (joint venture) drug group and the domestic drug group according to their current drug application. Two groups of patients were assessed by drug brand preference questionnaire and medication compliance questionnaire. Patients with brand preference in imported (joint venture) drugs group received rational use of limited medical resource and pharmacoeconomics education, and then switched with domestic drug for 8 weeks. Safety and efficacy were evaluated both before and after the drug switch.Results: Overall, there were 27% of patients in imported drug group and 35% of patients in domestic drug group have brand response, respectively. About 2/3 patients in both groups showed low or no brand response. The compliance was similar in both groups with no significant difference (6.04 ± 2.08 vs. 4.74 ± 2.13, respectively, P > 0.05). The efficacy of imported drug group was significantly better than of the domestic drug group. Correlation analysis showed that in imported (joint venture) drugs group, medication compliance was closely related with brand response, but negatively correlated with age and duration. In domestic drugs group, medication compliance was independent of brand response, but closely related with education, age, and duration. After drug switch with domestic drug on patients with brand response, patients continued to maintain good antidepressant effect, and no severe adverse reaction occurred.Conclusion: The results suggested that domestic drugs switch might be feasible for patients using imported drugs with brand response, while providing patients with rational use of drug education and psychological support. The medical staff should focus on medication education to help patients make better use of limited medical resources.

show abstract

Are generic and brand-name statins clinically equivalent? Evidence from a real data-base

Cited by 42 publications

References 31 publications

The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs

The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs

Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future

Drug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients

Contact Info

Product

Resources

About